These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 22325365)

  • 1. The clinical impact of DNA methylation frequencies of JAK2 negative regulators in patients with essential thrombocythemia.
    Födermayr M; Zach O; Huber M; Machherndl-Spandl S; Wölfl S; Bösmüller HC; Hasenschwandtner S; Burgstaller S; Krieger O; Lutz D; Weltermann A; Hauser H
    Leuk Res; 2012 May; 36(5):588-90. PubMed ID: 22325365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders.
    Capello D; Deambrogi C; Rossi D; Lischetti T; Piranda D; Cerri M; Spina V; Rasi S; Gaidano G; Lunghi M
    Br J Haematol; 2008 May; 141(4):504-11. PubMed ID: 18318760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders.
    Fourouclas N; Li J; Gilby DC; Campbell PJ; Beer PA; Boyd EM; Goodeve AC; Bareford D; Harrison CN; Reilly JT; Green AR; Bench AJ
    Haematologica; 2008 Nov; 93(11):1635-44. PubMed ID: 18815196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases.
    Teofili L; Martini M; Cenci T; Guidi F; Torti L; Giona F; Foà R; Leone G; Larocca LM
    Int J Cancer; 2008 Oct; 123(7):1586-92. PubMed ID: 18623127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenomic profiling in polycythaemia vera and essential thrombocythaemia shows low levels of aberrant DNA methylation.
    Barrio S; Gallardo M; Albizua E; Jiménez A; Rapado I; Ayala R; Gilsanz F; Martin-Subero JI; Martinez-Lopez J
    J Clin Pathol; 2011 Nov; 64(11):1010-3. PubMed ID: 21821860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased expression of PIAS1 and PIAS3 in essential thrombocythemia patients.
    Hsiao HH; Liu YC; Yang MY; Tsai YF; Liu TC; Chang CS; Lin SF
    Genet Mol Res; 2013 Nov; 12(4):5617-22. PubMed ID: 24301930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3.
    Hookham MB; Elliott J; Suessmuth Y; Staerk J; Ward AC; Vainchenker W; Percy MJ; McMullin MF; Constantinescu SN; Johnston JA
    Blood; 2007 Jun; 109(11):4924-9. PubMed ID: 17317861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-203 and miR-221 regulate SOCS1 and SOCS3 in essential thrombocythemia.
    Navarro A; Pairet S; Álvarez-Larrán A; Pons A; Ferrer G; Longarón R; Fernández-Rodríguez C; Camacho L; Monzó M; Besses C; Bellosillo B
    Blood Cancer J; 2016 Mar; 6(3):e406. PubMed ID: 26990535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma.
    Capello D; Gloghini A; Baldanzi G; Martini M; Deambrogi C; Lucioni M; Piranda D; Famà R; Graziani A; Spina M; Tirelli U; Paulli M; Larocca LM; Gaidano G; Carbone A; Sinigaglia F
    Hematol Oncol; 2013 Mar; 31(1):22-8. PubMed ID: 22488585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
    Gao SM; Chen CQ; Wang LY; Hong LL; Wu JB; Dong PH; Yu FJ
    Exp Hematol; 2013 Mar; 41(3):261-70.e4. PubMed ID: 23111066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation status of SOCS1 and SOCS3 in BCR-ABL negative and JAK2V617F negative chronic myeloproliferative neoplasms.
    Fernández-Mercado M; Cebrián V; Euba B; García-Granero M; Calasanz MJ; Novo FJ; Vizmanos JL; García-Delgado M
    Leuk Res; 2008 Oct; 32(10):1638-40. PubMed ID: 18440067
    [No Abstract]   [Full Text] [Related]  

  • 12. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders.
    Jost E; do O N; Dahl E; Maintz CE; Jousten P; Habets L; Wilop S; Herman JG; Osieka R; Galm O
    Leukemia; 2007 Mar; 21(3):505-10. PubMed ID: 17230231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling.
    Haan S; Wüller S; Kaczor J; Rolvering C; Nöcker T; Behrmann I; Haan C
    Oncogene; 2009 Aug; 28(34):3069-80. PubMed ID: 19543316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant signal transduction pathways in myeloproliferative neoplasms.
    Kota J; Caceres N; Constantinescu SN
    Leukemia; 2008 Oct; 22(10):1828-40. PubMed ID: 18769448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Hematology; 2008 Apr; 13(2):71-6. PubMed ID: 18616871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients.
    Trifa AP; Popp RA; Cucuianu A; Bănescu C; Tevet M; Martin B; Murat M; Vesa SC; Dima D; Cândea M; Militaru MS; Pop IV
    Br J Haematol; 2015 Jan; 168(1):151-3. PubMed ID: 25103987
    [No Abstract]   [Full Text] [Related]  

  • 17. Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients.
    Besses C; Alvarez-Larrán A; Martínez-Avilés L; Mojal S; Longarón R; Salar A; Florensa L; Serrano S; Bellosillo B
    Br J Haematol; 2011 Feb; 152(4):413-9. PubMed ID: 21219298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia.
    Nakatani T; Imamura T; Ishida H; Wakaizumi K; Yamamoto T; Otabe O; Ishigami T; Adachi S; Morimoto A
    Pediatr Blood Cancer; 2008 Dec; 51(6):802-5. PubMed ID: 18802948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood.
    Stevenson WS; Hoyt R; Bell A; Guipponi M; Juneja S; Grigg AP; Curtis DJ; Scott HS; Szer J; Alexander WS; Tuckfield A; Roberts AW
    Pathology; 2006 Aug; 38(4):336-42. PubMed ID: 16916724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.